Readycure

What Readycure does

Readycure (주식회사 레디큐어 / READYCURE Co., Ltd.) is a Seoul-based private health-tech startup founded in October 2021 by Professor Weon Kuu Chung, a radiation oncologist from Kyung Hee University Hospital. The company is developing HeLaXON, a low-dose digital X-ray treatment system for Alzheimer's disease and other neurodegenerative conditions. The core technology is a carbon nanotube (CNT)-based digital pulsed X-ray source architecture using ten simultaneous radiation sources (compared to a single source in conventional radiation equipment) to deliver ultra-low dose radiation (0.8-5% of doses used in brain metastasis treatment). The stated mechanism is restoring microglial cell function in the brain to address neurodegeneration at its root cause rather than managing symptoms pharmacologically.

The product portfolio includes HeLaXON 1X (clinical-stage treatment device), HeLaXON 2X (next-generation commercialization model with self-shielding structure and AI-based irradiation control), and EPATA 1X (brain drug delivery platform under joint development with Medical College of Georgia at Augusta University). The HeLaXON system integrates embedded AI for personalized treatment delivery and a cloud-based control platform intended to enable remote treatment services.

Readycure operates a pre-revenue business model targeting major hospitals, university medical centers, and dementia clinics. Revenue is intended to be generated through hardware sales of the HeLaXON device, maintenance/service contracts, and a future per-treatment or subscription model enabled by the cloud platform. Commercialization in Korea is structured through an MOU with DK Medical Solutions for nationwide installation and service support, with regulatory submissions planned for MFDS in Korea and FDA in the United States. The company has raised approximately 8.1B KRW (~6M USD) cumulatively across angel investment, Pre-A funding (FuturePlay lead), and government R&D grants.

Name

Readycure

Legal name

주식회사 레디큐어 (READYCURE Co., Ltd.)

Website

https://ready-cure.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales (HeLaXON): Revenue from selling HeLaXON low-dose digital X-ray dementia treatment devices to hospitals and medical institutions. The company is preparing for clinical trials and regulatory approval (MFDS in Korea, FDA in the US) before commercial launch.
2. Equipment Maintenance and Service Contracts: Ongoing maintenance, software updates, and operational support contracts with hospitals, to be handled through the DK Medical Solutions partnership network.
3. Per-Treatment Revenue: Cloud-based remote treatment delivery system enables per-treatment or subscription-based revenue model as a future stream once the platform is commercially deployed.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Readycure develops and sells HeLaXON, a medical device that delivers low-dose radiation therapy using carbon nanotube (CNT)-based multi-source digital X-ray technology to treat Alzheimer's disease and other neurodegenerative conditions. The device is controlled by an embedded AI system and linked to a cloud platform that enables remote, personalized treatment delivery. Revenue is generated through hospital device sales, maintenance/service contracts (via DK Medical Solutions), and a planned per-treatment/subscription model enabled by the cloud layer.

Product overview

Readycure is a health-tech company that has developed HeLaXON, a digital X-ray based treatment system for Alzheimer's disease. The product line includes HeLaXON 1X (clinical-stage low-dose X-ray treatment device) and HeLaXON 2X (next-generation commercialization model with AI-based control). The company uses CNT-based digital pulse X-ray technology and a cloud-based AI control system to deliver remote radiation therapy services. HeLaXON 1X is designed to restore brain immune function through multi-source radiation delivery, while HeLaXON 2X incorporates self-shielding and AI-based irradiation control for broader applications.

Differentiator

Problem solved

Functional benefit

Brands

• HeLaXON 1X: Low-dose X-ray based dementia treatment device currently preparing for clinical entry. Uses carbon nanotube-based digital pulse X-ray technology to restore brain immune function.
• HeLaXON 2X
• EPATA 1X

Products and services

• HeLaXON Medical device for treating Alzheimer's disease using digital pulse beam and digital X-ray technology based on carbon nanotube (CNT) sources, controlled by an AI-based system with embedded software, targeted at hospitals and medical institutions.
• HeLaXON 1X Low-dose X-ray based dementia treatment device that delivers optimal radiation through carbon nanotube-based digital X-ray sources to restore immune function in the brain, particularly microglial cells, for use by hospitals and specialized dementia clinics.
• HeLaXON 2X

Quantifiable outcome

• Up to 80% symptom reduction in dementia patients (vs 27% disease progression delay with current drugs)
• +3 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and secondary.

• DK Medical Solutions (DK메디칼솔루션)coreChannel Partner/ Reseller/ Distributor · 13 May 2026MOU signed for commercialization of the HeLaXON digital X-ray dementia treatment platform. DK Medical Solutions, with its nationwide medical imaging equipment service network, will handle hospital installation, maintenance, and operational support. The partnership covers equipment supply, hospital network integration, installation and maintenance, operational support, and joint marketing activities. Aims to connect clinical development with real-world hospital adoption.
• KIST Europe (Korea Institute of Science and Technology Europe)secondaryImplementation/ SI/ Consulting Partner · 1 October 2025Readycure participated in KIST Europe's acceleration program in Saarbrücken, Germany (October 26 - November 1, 2025). The program included IR pitching, technology and marketability consulting, and networking with local institutions and experts. Part of KIST Innovation & Startup Division's global support initiative for Korean technology startups entering the European market.
• CUREVERSEsecondaryTechnology or Integration · 21 April 2025MOU signed for technical and business cooperation. Collaboration focuses on technology development and business synergy between the two companies' platforms.
• JNPMEDI-MCRA (an IQVIA business)secondaryImplementation/ SI/ Consulting Partner · 1 January 2025Participation in JNPMEDI-MCRA clinical trial collaboration program. JNPMEDI provides AI-based clinical trial consulting and solutions services, supporting Readycure's clinical development and regulatory approval process.
• Korea Atomic Energy Research Institute - Advanced Radiation Research Institute (한국원자력연구원 첨단방사선연구소)coreStrategic or Co-development PartnerMOA (Memorandum of Agreement) signed with the Advanced Radiation Research Institute of KAERI for joint research, collaborative development of commercialization items, and regular consultation body operation. Focuses on low-dose radiation technology development for treating intractable diseases and medical device development.
• Medical College of Georgia, Augusta UniversitycoreStrategic or Co-development PartnerInternational R&D collaboration partner under the Ministry of SMEs and Startups' Global Cooperation R&D project (1.5B KRW). Jointly developing 'EPATA 1X' brain drug delivery platform for treating neurodegenerative diseases.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Elekta: Swedish-headquartered incumbent in linear accelerators, Gamma Knife radiosurgery, and brachytherapy. Elekta's Gamma Knife platform in particular targets intracranial conditions, giving it adjacent expertise in brain-focused radiation therapy that could be redirected toward dementia applications.
• Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology hardware and software, now part of Siemens Healthineers. While Varian focuses on high-dose cancer radiotherapy rather than low-dose dementia applications, it represents the dominant installed-base and channel competitor Readycure will face as it commercializes any radiation therapy device in hospitals.

Direct peers

• Novocure: Commercial-stage company treating solid tumors with Tumor Treating Fields, a non-invasive, non-pharmacological physical modality delivered via wearable devices. Novocure is the most analogous business model: a non-drug, device-based therapy for serious diseases sold to hospitals and supported by clinical evidence.
• ViewRay: Developer of MRIdian, an MRI-guided radiation therapy system. ViewRay competes on integrating imaging intelligence with radiation delivery, conceptually parallel to Readycure's AI-controlled multi-source CNT platform and facing similar hospital-channel dynamics.
• Accuray: Developer of CyberKnife and TomoTherapy radiation therapy systems used for precise, targeted treatment delivery. Like Readycure, Accuray competes on novel device architectures that improve targeting and reduce collateral exposure, making it the closest direct peer in radiation therapy hardware innovation.

Others

• Hippocratic AI: Adjacent emerging company in the Korean/international health-tech ecosystem pursuing AI-driven clinical applications. Included as a thematic peer given overlapping healthcare-AI positioning, though its solutions are software-only and not directly comparable to radiation therapy hardware.

Emerging players

• Brainlab: Munich-based developer of image-guided surgery and radiosurgery software/hardware with deep neurosurgery and cranial radiotherapy exposure. Brainlab's cranial radiosurgery adjacency makes it a comparable for the procedural and software side of Readycure's offering.
• Mevion Medical Systems: Smaller US-based manufacturer of compact proton therapy systems targeting community hospitals. Mevion competes on novel radiation source architectures and reducing the footprint/cost of advanced radiotherapy, structurally similar to Readycure's CNT-based miniaturization strategy.
• CUREVERSE: Korean counterpart with a signed MOU with Readycure for technical and business cooperation. CUREVERSE works on related neurodegenerative disease platforms, making it both a partner and a closely adjacent emerging peer in the Korean brain-therapy device ecosystem.
• Alpha Tau Medical: Clinical-stage company developing alpha-emitter intratumoral radiation therapy (DaRT) for solid tumors. Alpha Tau exemplifies a small-cap medical device company commercializing a novel radiation modality through hospital channels, similar to Readycure's commercialization path.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@%EC%A3%BC%EB%A0%88%EB%94%94%ED%81%90%EC%96%B4

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Readycure